Frida LIND-HOLM MOGENSEN

Microglia programs under PARK7/DJ-1 deficiency, a genetic cause of Parkinson’s disease, in a DJ-1 mouse model and human induced pluripotent stem cell-derived microglia It is increasingly evident that dysregulated microglia are implicated in neurodegenerative diseases, such as Parkinson’s disease (PD). The majority of PD cases are idiopathic but in around 10% of patients suffering from … Continued

Anne-Marie HANFF

Development of a new Functional Mobility Composite Score in Parkinson’s disease: Sample characteristics of the NCER-PD cohort and exploratory analyses on internal consistency and stability OBJECTIVES Describe the characteristics of people with typical Parkinson’s disease (PD) participating in the NCER cohort. Explore the internal consistency and stability of the Functional Mobility Composite Score (FMCS). BACKGROUND … Continued

Laure PAULY

Exploring the retrograde procedural memory in Parkinson’s disease in the Luxembourg Parkinson’s Study Objective: The present project focused on developing a neuropsychological tool for the evaluation of the retrograde procedural memory in Parkinson’s disease. Background: Many daily life activities such as playing the piano, driving a manual car or tying one’s shoes rely on the … Continued

Corrado AMELI

Combinatory effect of proteinopathies on microglia responses in mixed-dementia hippocampus The hippocampus deterioration is at the centre of memory decline in the most common age- and dementia-related neurodegenerative diseases: Alzheimer’s disease (AD) and Dementia with Lewy Bodies (DLB). However, its subregional atrophy pattern differs between both diseases, the CA1 subfield being more severely affected in … Continued

Axel CHEMLA

Analyzing the role of Parkinson’s disease-associated RHOT1/Miro1 variants in vitro and in vivo Background: Many studies highlighted the involvement of the protein Miro1 in regulating mitochondrial quality control, transport, and homeostasis as well as cellular calcium handling, which are all mechanisms associated with Parkinson’s Disease (PD) pathogenesis. Both fibroblasts and neurons from PD patients display … Continued

Francesca Maria STEFANIZZI

Circular RNAs to predict outcome after out-of-hospital cardiac arrest More than 400,000 cases of cardiac arrest (CA) occur each year in Europe. Among patients admitted to intensive care unit, the mortality rate averages 50%. Accurate prediction of outcomes would enable health care adaptation. Therefore, the discovery of new specific biomarkers could improve the prognosis of … Continued

Kristopher SCHMIT

Alpha-synuclein-induced patholigies in brain and gut by curli and a fibre-deprived diet in a transgenic mouse model of Parkinson’s disease Parkinson’s disease (PD) is a complex, multi-factorial disease for which multiple mechanisms have been postulated contribute to its physiopathology. We hypothesize that PD can be triggered and driven by a combinatorial effect of reduced gut … Continued

Kyriaki BARMPA

Building human Midbrain-Striatum assembloids for in vitro modeling of Parkinson’s disease Human brain organoids have a great potential for in vitro modelling of neurodegenerative diseases such as Parkinson’s disease (PD). Specifically, midbrain organoids have been a useful tool for studying the disease hallmarks, such as dopaminergic neuron’s degeneration and α-synuclein aggregation. However, the midbrain is … Continued

Borja GOMEZ RAMOS

Integrated genomics for the identification of novel factors controlling midbrain dopaminergic neuron differentiation Objective: In this project, we are studying the gene regulatory program underlying midbrain dopaminergic (mDAN) differentiation and identity for the identification of novel factors controlling this process. Background: Induced pluripotent stem cell (iPSC) technology allows us to reprogram human somatic cells into … Continued

Sreyoshi CHATTERJEE

Gene prioritization through comparative analyses of focal and generalized epilepsies Genetic Generalized Epilepsy (GGE) is a well characterized epileptic disorder and represents 30 percent of all epilepsies. Studies in epileptogenesis have confirmed several dysregulated genes (e.g., HCN1, KCND2) which are also primarily mutated in genetic epilepsies. Our aim is to explore this connection of genes … Continued